- Home
- TVGN vs KRSA Comparison
TVGN vs KRSA Comparison
Compare TVGN & KRSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVGN | KRSA |
|---|---|---|
| Founded | 2020 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.3M | 1.5B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TVGN | KRSA |
|---|---|---|
| Price | $6.57 | $31.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.00 |
| AVG Volume (30 Days) | 4.9K | ★ 112.3K |
| Earning Date | 11-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.26 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,074,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $0.14 | $29.03 |
| 52 Week High | $32.90 | $37.27 |
Technical Indicators
Market Signals| Indicator | TVGN | KRSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.30 | 43.15 |
| Support Level | $6.15 | $29.98 |
| Resistance Level | $7.65 | $36.30 |
| Average True Range (ATR) | 0.47 | 2.56 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 43.45 | 17.27 |
Price Performance
Historical ComparisonAbout TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.
About KRSA Korsana Biosciences Inc. Common Stock
Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.